Erratum


An error in the indication for Solaraze Gel was published in this work. The sentence under the heading “The rationale for topical NSAIDs” that states “At present, four products containing diclofenac for topical application have been approved by the US Food and Drug Administration for the treatment of OA” should in fact read as “At present, four products containing diclofenac for topical application have been approved by the US Food and Drug Administration.”

Solaraze Gel is only indicated for actinic keratosis and Flector Patch is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. Though clinical trials with Flector for patients with knee OA have been published, it is not officially approved for use in OA.

Currently only Pennsaid and Voltaren are indicated for OA by the US Food and Drug Administration.